FDA scientists have flagged serious doubts about whether peptides — the trendy biological molecules that Health and Human Services Secretary Robert F. Kennedy Jr. has championed — are actually safe or effective, according to internal agency review documents.
The documents, released ahead of a scheduled advisory panel meeting later this month, found the research backing peptides lacks good evidence on either front. No strong data on efficacy. No solid safety record. Yet the panel is being asked to consider making the compounds easier to obtain — a move that would expand access well before that scientific gap is closed.
What the documents say
The FDA staff review didn’t identify a class of peptides that cleared the bar. The documents describe the body of existing research as insufficient — not a close call, but a straightforward finding that the evidence isn’t there. Peptides are short chains of amino acids that have attracted intense interest from wellness circles and some corners of federal health leadership, with Kennedy among their more prominent advocates.
The advisory panel meeting is set for later in June 2026. If the panel recommends loosening access, it would mark a sharp departure from the FDA’s own scientists’ read of the data — and it would put the agency’s leadership in the position of overriding its staff on a question that has drawn public attention largely because of Kennedy’s backing.
It isn’t clear yet what weight the panel will give the staff documents, or whether the agency’s leadership would act on a recommendation that runs counter to them. The panel’s composition and its full charge haven’t been detailed in publicly available materials.
Peptides are already available through compounding pharmacies in some formulations, and the question before the panel is essentially whether that access should be broadened. Compounded drugs aren’t subject to the same pre-market approval process as standard FDA-approved medications — which is part of why the safety and efficacy question matters here more than it might in other contexts.
